Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK2 | P49137 | 17/20 | 0.56 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | SLC11A2 | P49281 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4444521 | 0.94 | MAPKAPK2 (0.55) | MAPKAPK2SLC11A2THRBTGFBR1 | |
| SCHEMBL4264450 | 0.90 | MAPKAPK2 (0.45) | MAPKAPK2TGFBR1 | |
| SCHEMBL6792722 | 0.89 | MAPKAPK2 (0.44) | MAPKAPK2 | |
| SCHEMBL6794024 | 0.87 | MAPKAPK2 (0.41) | MAPKAPK2SLC11A2 | |
| SCHEMBL4265876 | 0.86 | MAPKAPK2 (0.41) | MAPKAPK2 | |
| SCHEMBL6793907 | 0.85 | MAPKAPK2 (0.41) | MAPKAPK2 | |
| SCHEMBL4267617 | 0.85 | MAPKAPK2 (0.41) | MAPKAPK2 | |
| SCHEMBL4267623 | 0.85 | MAPKAPK2 (0.41) | MAPKAPK2 | |
| SCHEMBL4267668 | 0.85 | MAPKAPK2 (0.38) | MAPKAPK2 | |
| SCHEMBL4270927 | 0.85 | MAPKAPK2 (0.41) | MAPKAPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | PHARMACIA CORPORATION | 2004-07-01 | — | — | US | claimed |
| US-9023787-B2 | MAPKAP kinase-2 as a specific target for blocking proliferation of P53-defective | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2015-05-05 | — | — | US | disclosed |
| US-20140037755-A1 | Mapkap Kinase-2 as a Specific Target for Blocking Proliferation of P53-Defective Cells | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2014-02-06 | — | — | US | disclosed |
| US-8440610-B2 | Mapkap kinase-2 as a specific target for blocking proliferation of P53-defective cells | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2013-05-14 | — | — | US | disclosed |
| US-20120252737-A1 | Methods for Diagnosing and Treating Cancer | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2012-10-04 | — | — | US | disclosed |
| US-20090181468-A1 | Methods and compositions for treating cellular proliferative diseases | YAFFE MICHAEL B | 2009-07-16 | — | — | US | disclosed |
| US-20090010927-A1 | Mapkap kinase-2 as a specific target for blocking proliferation of P53-defective cells | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-01-08 | — | — | US | disclosed |
| US-20060115453-A1 | Methods and compositions for treating cellular proliferative diseases | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2006-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060115453-A1 | Methods and compositions for treating cellular proliferative diseases | MKI67, TP53, CCNC | MAPKAPK2 1486/4885PARP1 628/4885SLC11A2 2377/4885 |
| US-20140037755-A1 | Mapkap Kinase-2 as a Specific Target for Blocking Proliferation of P53-Defective Cells | MAPKAPK2, MAPKAP1, MAP3K2 | MAPKAPK2 1/4885PARP1 2171/4885SLC11A2 3982/4885 |
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | MKNK2, MAPKAPK2, MAP3K2 | MAPKAPK2 2/4885PARP1 2423/4885SLC11A2 4758/4885 |
| US-20090010927-A1 | Mapkap kinase-2 as a specific target for blocking proliferation of P53-defective cells | MAPKAPK2, MAPKAP1, MAP3K2 | MAPKAPK2 1/4885PARP1 2171/4885SLC11A2 3982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.